BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//MedNet - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MedNet
X-ORIGINAL-URL:https://mednetus.net
X-WR-CALDESC:Events for MedNet
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250620T080000
DTEND;TZID=America/New_York:20250620T170000
DTSTAMP:20260423T152955
CREATED:20250620T063840Z
LAST-MODIFIED:20250620T063840Z
UID:10000007-1750406400-1750438800@mednetus.net
SUMMARY:Glaucoma Management: Understanding Risk Factors\, Screening and Treatment Options
DESCRIPTION:CME | CNE 1.50 Credits \nWebcast \nTime to Complete: 90 minutes \nReleased: May 15\, 2024 \nExpires: May 15\, 2025 \nMaximum Credits:\n1.50 / AMA PRA Category 1 CreditsTM\n1.50 / ANCC Contact Hours \nProgram Description \nA glaucoma is a heterogeneous group of diseases that has become a significant cause of irreversible blindness worldwide. A glaucoma group of optic neuropathies is characterized by progressive degeneration of retinal ganglion cells. These are central nervous system neurons with cell bodies in the inner retina and axons in the optic nerve. Degeneration of these nerves results in cupping\, a characteristic optic disc appearance\, and visual loss. The biological basis of glaucoma is poorly understood\, and the factors contributing to its progression have not been fully characterized. \nIntended Audience \nOphthalmologists\, retina specialists\, physician assistants\, and nurse practitioners in Ophthalmology clinics \nCommercial Supporter \nThis activity is supported by an educational grant from Alcon Vision. \nEducational Objectives \nUpon completion of the educational activity\, participants should be able to: \n\nSummarize the pathophysiology\, risk factors\, and screening of glaucoma\nAssess clinical trial data on topical agents in the management of glaucoma\nAppraise clinical trial data on sustained-release drug delivery systems in the management of glaucoma\nAnalyze inequities in the diagnosis and management of glaucoma in African-American and Hispanic patients\n\nAccredited Providers \nThe University of Cincinnati\, Amedco\, and MedNet have collaborated to design and execute this activity. \n \n \nJoint Accreditation Statement \nIn support of improving patient care\, this activity has been planned and implemented by Amedco LLC and MedNet\, LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. \nPhysicians (ACCME) Credit Designation \nDesignation Statement \nAmedco LLC designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nNurses (ANCC) Credit Designation \nDesignation Statement \nAmedco LLC designates this enduring material activity for a maximum of 1.50 ANCC contact hours. \nAdditional Credit Information \nPhysician Assistants/Associates\nAAPA accepts AMA PRA Category 1 Credit(s)TM for the PRA from organizations accredited by ACCME. Maximum of 1.50 hours. \nNurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.50 hours. \nConflict of Interests Policy \nIt is the policy of the Amedco to ensure activity content is balanced\, independent\, objective and based on scientific best-evidence. All persons in a position to control content (i.e.\, course director\, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation. \nEvery person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose. \nPlanners and Managers Disclosures \nThe planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: \nAll relevant relationships have been reviewed and mitigated. \nKamatham A. Naidu\, PhD (MedNet)\, has no relevant financial relationships\nBrian Waggoner (MedNet) has no relevant financial relationships to disclose.\nJustin Kaiser (Amedco) has no relevant financial relationships to disclose. \nDisclosure of Unlabeled Use \nIt is the policy of the Amedeo to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label\, unlabeled\, experimental\, and/or investigational (not FDA approved) and of any limitations on the information that is presented\, such as data that are preliminary or that represent ongoing research\, interim analyses\, and/or unsupported opinion. \nEach speaker reported he/she will notify the audience if/when discussion includes off-label\, unlabeled\, experimental\, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation. \nDisclaimer \nThe information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. \nNon-Endorsement of Products \nAmedco do not imply either real or implied endorsement of any product\, service\, or company referred to in this educational activity. \nFaculty \nDavid S. Friedman\, MD\, MPH\, PhD\nAlbert and Diane Kaneb Professor\nDirector\, Glaucoma Service\nCo-Director\, Glaucoma Center of Excellence\, Massachusetts Eye and Ear\nBoston\, MA \nDr. Friedman reported that he received consultant fees from Thea Pharmaceuticals and Health Advances LLC. Slides were provided by Janey Wiggs\, Inas Aboobakar and Nazlee Zebardast\, Tom Johnson\, Ian Pitha\, and Henry Jampel. \nKaren Allison MD\, MBA\, FACS\nAssociate Professor of Clinical Ophthalmology\nUniversity of Rochester\, Flaum Eye Institute\nRochester\, NY \nDr. Allison reported no relevant relationships. \nInstructions \nIn order to receive CME/CE credits\, participants must complete the pre-assessment questions\, post-assessment\, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript\, which you can access at any time. \nFor information about the accreditation of this program\, please contact Justin Kaiser (justin@amedcoe-mail.com; 651-789-3717). \nPrivacy Policy \nAmedco observes privacy and confidentiality of CME/CE information and personal information of CME/CE participants. Third parties receive only aggregated data about CME/CE activities relevant to their interests and/or the activities they support. \nmyCME privacy policy
URL:https://mednetus.net/event/glaucoma-management-understanding-risk-factors-screening-and-treatment-options/
CATEGORIES:Webcast
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/kqi2sdpiz8s7-800x450-Endur.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250620T080000
DTEND;TZID=America/New_York:20250620T170000
DTSTAMP:20260423T152955
CREATED:20250620T064145Z
LAST-MODIFIED:20250620T064145Z
UID:10000008-1750406400-1750438800@mednetus.net
SUMMARY:New Prospects in Blood-based Biomarkers and Disease-Modifying Anti-Amyloid Antibody Therapies for Early-Stage Alzheimer’s Disease
DESCRIPTION:CME | 1.50 Credits \nWebcast \nTime to Complete: 90 minutes \nReleased: February 16\, 2024 \nExpires: February 16\, 2025 \nMaximum Credits:\n1.50 / AMA PRA Category 1 CreditsTM \nProgram Description \nThis webcast provides an update on the blood-based markers (BBMs) improve randomized clinical trials (RCTs) design and conduct of Alzheimer’s disease. It remains to be determined if the data available on BBMs are strong enough to replace CSF and PET biomarkers as entry criteria and monitoring tools in RCTs. Strategies to optimize and guide disease-modifying anti-amyloid antibody (AAA) therapies based on BBMs in managing patients with early-stage AD. \nIntended Audience \nNeurologists\, nurse practitioners\, and physician assistants involved in Alzheimer’s disease patient care. \nCommercial Supporter \nThis activity is supported by an educational grant from Eisai\, Inc. \nEducational Objectives \nUpon completion of the educational activity\, participants should be able to: \n\nAssess the blood-based biomarkers in diagnosing early-stage AD and its utility in the prevention.\nIdentify strategies to optimize disease-modifying anti-amyloid antibody (AAA) therapies in managing patients with early-stage AD.\n\nAccredited Providers \nThe University of Cincinnati\, Amedco\, and MedNet have collaborated to design and execute this activity. \n \n \nPhysicians (ACCME) Credit \n\nAccreditation Statement \nIn support of improving patient care\, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163. \n\n\nDesignation Statement \nAmedco LLC designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\nAdditional Credit Information \nThrough an agreement between the American Medical Association (AMA) and the European Union of Medical Specialists\, physicians and healthcare providers may convert CME/CE PRA Category 1 CreditsTM to an equivalent number of European CME Credits® (ECMECs®). The UEMS-EACCME® has mutual recognition agreements with the AMA for live events and e-learning materials. \nPhysician Assistants/Associates\nPAs may claim a maximum of 1.50 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)TM from organizations accredited by ACCME or a recognized state medical society. \nNurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.50 hours. \nDisclosures of Relationships with Ineligible Companies Policy \nIt is the policy of the Amedco to ensure activity content is balanced\, independent\, objective\, and based on scientific best-evidence. All persons in a position to control content (i.e.\, course director\, planning committee member\, and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation. \nPlanners and Managers Disclosures \nThe planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: \nAll relevant relationships have been reviewed and mitigated. \nKamatham A. Naidu\, PhD (MedNet)\, has no relevant financial relationships\nBrian Waggoner (MedNet) has no relevant financial relationships to disclose.\nSheryl Morgan (Amedeo) has no relevant financial relationships to disclose. \nOff-Label Disclosure Statement \nFaculty members are required to inform the audience when they are discussing off-label\, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity. \nFaculty \nJeremy Pruzin MD\nCognitive/Behavioral Neurologist\nBanner Alzheimer’s Institute\nPhoenix\, AZ \nDr. Pruzin discloses that he is on the advisory board of Eisai\, Inc. \nMarwan Noel Sabbagh MD\, FAAN\, FANA\nMoreno Family Chair of Alzheimer’s Research\nVice Chair for Research and Professor of Neurology\nDirector of the Applied Alzheimer’s Research Laboratory\nPhoenix\, AZ \nDr. Sabbagh discloses the following:\nOwnership interest (Stock or stock options): NeuroTau\, Optimal Cognitive Health Company\, uMethod Health\, Versanum\, Athira\, TransDermix\, Seq BioMarque\, NeuroReserve\, Lighthouse Pharmaceuticals\, Alzheon\, Reservoir Neuroscience\nConsulting: Roche-Genentech\, Eisai\, Lilly\, Synaptogenix\, NeuroTherapia\, T3D\, Signant Health\, Novo Nordisk\, Corium\, Prothena\, KeiferRx\, Anavex\, Cognito Therapeutics\nRoyalties: Humanix\nBoard of Director: EIP Pharma\nGrants and other Support:\nPI: RO 1 AG059008\nSABBAGH\, MARWAN (PI)\n09/01/18-05/31/24\nA Phase II Clinical Trial for the Assessment of Safety\, Tolerability\, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease \nLBDA1811MS\nSABBAGH\, MARWAN (PI)\n05/15117-04/30/23\nResearch Center of Excellence (RCOE) designation \nSite PI TRC-DS 1R61AG066543-01 (R61AG066543)\nSite PI:ADRC- 1P30AG072980-01\nSite PI: ADNI-U19AG024904 \nGC-2013717\nSABBAGH\, MARWAN (PI)\n01/01/23-12/31127\nAssessment of Lenalidomide for Alzheimer’s Disease \nR01 AG073212\nSABBAGH\, MARWAN (PI)\nWILSON\, JEFFREY (MPI)\nDECOURT\, BORIS (MPI)\nRepurposing Siponimod for Alzheimer’s Disease\n4/1/21- 3/30/26 \nInstructions \nIn order to receive CME/CE credits\, participants must complete the pre-assessment questions\, post-assessment\, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript\, which you can access at any time. \nANCC – Amedco\nPhone Number: 651-789-3730\nE-Mail: Sheryl@AmedcoEmail.com \nPrivacy Policy \nmyCME privacy policy
URL:https://mednetus.net/event/new-prospects-in-blood-based-biomarkers-and-disease-modifying-anti-amyloid-antibody-therapies-for-early-stage-alzheimers-disease/
CATEGORIES:Webcast
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/4a8cb550s6og-Neurons_800x450_endur.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250620T080000
DTEND;TZID=America/New_York:20250620T170000
DTSTAMP:20260423T152955
CREATED:20250620T064422Z
LAST-MODIFIED:20250620T064422Z
UID:10000009-1750406400-1750438800@mednetus.net
SUMMARY:Sustained-Release Drug Delivery System in the Management of Glaucoma
DESCRIPTION:CME | CNE 1.25 Credits \nWebcast \nTime to Complete: 75 minutes \nReleased: March 15\, 2023 \nExpires: March 15\, 2024 \nMaximum Credits:\n1.25 / AMA PRA Category 1 CreditsTM\n1.25 / ANCC Contact Hours \nProgram Description \nA glaucoma is a heterogeneous group of diseases that has become a significant cause of irreversible blindness worldwide. A glaucoma group of optic neuropathies is characterized by progressive degeneration of retinal ganglion cells. These are central nervous system neurons with cell bodies in the inner retina and axons in the optic nerve. Degeneration of these nerves results in cupping\, a characteristic optic disc appearance\, and visual loss. The biological basis of glaucoma is poorly understood\, and the factors contributing to its progression have not been fully characterized. \nIntended Audience \nOphthalmologists\, retina specialists\, physician assistants and nurse practitioners in Ophthalmology clinics \nCommercial Supporter \nThis activity is supported by an educational grant from AbbVie Inc. \nEducational Objectives \nUpon completion of the educational activity\, participants should be able to: \n\nSummarize the pathophysiology of glaucoma development\nAssess clinical trial data on new sustained-release drug delivery system in the management of glaucoma\n\nAccredited Providers \nThis activity is provided by Amedco\, a CME/CE company\, and MedNet. \n      \nJoint Accreditation Statement \nIn support of improving patient care\, this activity has been planned and implemented by Amedco LLC and MedNet\, LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. \nPhysicians (ACCME) Credit Designation \nDesignation Statement \nAmedco LLC designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nNurses (ANCC) Credit Designation \nDesignation Statement \nAmedco LLC designates this enduring material activity for a maximum of 1.25 ANCC contact hours. \nAdditional Credit Information \nNote to Physician Assistants\nAAPA accepts AMA PRA Category 1 Credit(s)TM for the PRA from organizations accredited by ACCME. Maximum of 1.25 hours. \nNote to Nurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.25 hours. \nConflicts of Interest Policy \nIt is the policy of the Amedco to ensure activity content is balanced\, independent\, objective and based on scientific best-evidence. All persons in a position to control content (i.e.\, course director\, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation. \nEvery person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose. \nPlanners’ and Managers’ Disclosures \nThe planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast: \nKamatham A. Naidu\, PhD (MedNet) has no relevant financial relationships.\nBrian Waggoner (MedNet) has no relevant financial relationships to disclose.\nSheryl Morgan (Amedco) has no relevant financial relationships to disclose. \nDisclosure of Unlabeled Use \nIt is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label\, unlabeled\, experimental\, and/or investigational (not FDA approved) and of any limitations on the information that is presented\, such as data that are preliminary or that represent ongoing research\, interim analyses\, and/or unsupported opinion. \nEach speaker reported he/she will notify the audience if/when discussion includes off-label\, unlabeled\, experimental\, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation. \nDisclaimer \nThe information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. \nNon-Endorsement of Products \nAmedco do not imply either real or implied endorsement of any product\, service\, or company referred to in this educational activity.
URL:https://mednetus.net/event/sustained-release-drug-delivery-system-in-the-management-of-glaucoma/
CATEGORIES:Webcast
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/u7t0nqp7bktz-800x450Endur.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250620T080000
DTEND;TZID=America/New_York:20250620T170000
DTSTAMP:20260423T152955
CREATED:20250620T064702Z
LAST-MODIFIED:20250620T064702Z
UID:10000010-1750406400-1750438800@mednetus.net
SUMMARY:New Paradigms in the Clinical Practice of Inflammatory Bowel Diseases
DESCRIPTION:CME | CNE 1.25 Credits \nWebcast \nTime to Complete: 1.25 hours \nReleased: December 14\, 2022 \nExpires: December 14\, 2023 \nMaximum Credits:\n1.25 / AMA PRA Category 1 CreditsTM\n1.25 / ANCC Contact Hours \nProgram Description \nInflammatory bowel diseases (IBD)\, commonly categorized as Crohn’s disease (CD) and ulcerative colitis (UC)\, are immune mediated chronic inflammatory disorders of the gastrointestinal tract. The etiopathogenesis is multifactorial\, with different environmental\, genetic\, immune mediated\, and gut microbial factors playing an important role. The current therapy goals are to improve clinical symptoms\, control inflammation\, prevent complications\, and improve quality of life. The field of IBD therapeutics has seen tremendous improvements\, and the efficacy of new drug targets such as IL-12/IL-23\, the JAK/STAT pathway\, and S1P has been established. Extra-intestinal manifestations (EIMs) are a common complication of IBD\, affecting up to half of the patients. Despite their high prevalence\, information on standardized definitions\, diagnostic strategies\, and treatment targets is limited. \nIntended Audience \nGastroenterologists\, internal medicine specialists\, primary care physicians\, nurse practitioners\, physician assistants\, and nurses caring for patients with IBDs. \nCommercial Supporters \nThis activity is supported by an educational grant from Pfizer Inc. and Bristol Myers Squibb. \nEducational Objectives \nUpon completion of the educational activity\, participants should be able to: \n\nIncorporate biologics\, small molecule inhibitors\, and biosimilars in the treatment of inflammatory bowel diseases (IBD)\nAssess the interdisciplinary management strategies of extra-intestinal manifestations in people living with IBD\n\nAccredited Providers \nThis activity is provided by Amedco\, a CME/CE company\, and MedNet. \n       \nJoint Accreditation Statement \n \nIn support of improving patient care\, this activity has been planned and implemented by Amedco LLC and MedNet LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to provide continuing education for the healthcare team. \nPhysicians (ACCME) Credit Designation \nDesignation Statement \nAmedco LLC designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nNurses (ANCC) Credit Designation \nDesignation Statement \nAmedco LLC designates this activity for a maximum of 1.25 ANCC contact hours. \nAdditional Credit Information \nNote to Physician Assistants\nPAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditsTM from organizations accredited by ACCME or a recognized state medical society \nNote to Nurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allows reciprocity for AANPCP continuing education credit for a maximum of 1.25 hours. \nConflicts of Interest Policy \nIt is the policy of Amedco and MedNet to ensure activity content is balanced\, independent\, objective\, and based on scientific best evidence. All persons in a position to control content (i.e.\, course director\, planning committee member\, and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to his/her presentation content. \nEvery person in a position to control content reported he/she does not have any relevant financial relationships with the industry (relative to the content of his/her presentation) to disclose. \nPlanners’ and Managers’ Disclosures \nMiguel Regueiro\, MD\, discloses the following:\nUnrestricted Educational Grants: Abbvie\, Janssen\, UCB\, Pfizer\, Takeda\, Celgene\, Genentech\, Gilead\, BMS\, Lilly\nAdvisory Boards and Consultant: Abbvie\, Janssen\, UCB\, Takeda\, Pfizer\, Miraca Labs\, Amgen\, Celgene\, Seres\, Allergan\, Genentech\, Gilead\, Salix\, Prometheus\, Lilly\, TARGET Pharma Solutions\, ALFASIGMA\, S.p.A.\, BMS\nCME Companies: CME Outfitters\, lmedex\, Gl Health Foundation (GiHF)\, Cornerstones\, Remedy\, MJH life sciences\, Medscape\, MDEducation\, WebMD\, HMPGiobal\nRoyalties and Editorships: Wolters Kluwer Health as Author/Editor of UpToDate\, Crohn’s and Colitis Foundation as Editor-in-Chief\, CC360 \nKamatham A. Naidu\, PhD\, (MedNet) has no relevant financial relationships.\nBrian Waggoner (MedNet) has no relevant financial relationships to disclose.\nSheryl Morgan (Amedco) has no relevant financial relationships to disclose. \nDisclosure of Unlabeled Use \nIt is the policy of Amedco and Medical Media Holdings to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label\, unlabeled\, experimental\, and/or investigational (not FDA approved) and of any limitations on the information that is presented\, such as data that are preliminary or that represent ongoing research\, interim analyses\, and/or unsupported opinion. \nEach speaker reported he/she would notify the audience if/when the discussion includes off-label\, unlabeled\, experimental\, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation. \nDisclaimer \nThe information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. \nFaculty \nMiguel Regueiro\, MD\nProfessor\nDepartment of Medicine\,\nCleveland Clinic Lerner College of Medicine of Case Western Reserve University\nCleveland\, OH \nDr. Regueiro discloses that he received unrestricted educational grants from Abbvie\, Janssen\, UCB\, Pfizer\, Takeda\, Celgene\, Genentech\, Gilead\, BMS\, Lilly; on the advisory boards and consultant of Abbvie\, Janssen\, UCB\, Takeda\, Pfizer\, Miraca Labs\, Amgen\, Celgene\, Seres\, Allergan\, Genentech\, Gilead\, Salix\, Prometheus\, Lilly\, TARGET Pharma Solutions\, ALFASIGMA\, S.p.A.\, BMS; participated in CME companies: CME Outfitters\, lmedex\, Gl Health Foundation (GiHF)\, Cornerstones\, Remedy\, MJH life sciences\, Medscape\, MDEducation\, WebMD\, HMPGiobal; and holds royalties and editorships: Wolters Kluwer Health as Author/Editor of UpToDate\, Crohn’s and Colitis Foundation as Editor-in-Chief\, CC360Pfizer\, X4 Pharma\, Infinity\, AstraZeneca\, Bayer\, Merck\, ABX\, Curium\, Astellas\, Dendreon. \nFrancis Farraye\, MD\, MSc\nDirector\nInflammatory Bowel Disease Center\nDivision of Gastroenterology and Hepatology\nMayo Clinic\nJacksonville\, FL \nDr. Farraye discloses that he was on the advisory boards of Braintree\, BMS\, GI Reviewers\, GSK\, Iterative Health\, Janssen\, Pfizer\, Sebela; holds stock in Innovation pharmaceuticals; and DSMB with Adiso Therapeutics\, and Lilly. \nInstructions \nIn order to receive CME/CE credits\, participants must complete the pre-assessment questions\, post-assessment\, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript\, which you can access at any time. \nFor information about the accreditation of this program\, please contact Sheryl Morgan (651-789-3730; email: Sheryl@AmedcoEmail.com \nPrivacy Policy \nAmedco observes privacy and confidentiality of CME/CE information and personal information of CME/CE participants. Third parties receive only aggregated data about CME/CE activities that are relevant to their interests and/or the activities they support. \nmyCME privacy policy
URL:https://mednetus.net/event/new-paradigms-in-the-clinical-practice-of-inflammatory-bowel-diseases/
CATEGORIES:Webcast
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/3kvr1p7xc7dk-Oveviewpg_800x450.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250620T080000
DTEND;TZID=America/New_York:20250620T170000
DTSTAMP:20260423T152955
CREATED:20250620T072436Z
LAST-MODIFIED:20250620T072436Z
UID:10000014-1750406400-1750438800@mednetus.net
SUMMARY:Advances in the Understanding of Etiology\, Evaluation\, and Management of Neurotrophic Keratitis
DESCRIPTION:March 1\, 2025 \nTake Me to the Event Registration \nEVENT Summary \nDates \nSaturday\, March 1\, 2025\, 10:00 AM ET\, 9:00 AM CT\, 8:00 AM MT\, and 7:00 AM PT \nLocation \nVirtual \nTarget Audience \nOphthalmologists\, optometrists\, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with neurotrophic keratitis \nFormat \nZoom Webinar \nCredits \n1.25 / AMA PRA Category 1 Credit(s)TM\n1.25 / COPE CE Credits \nCost \nFree \n\n\n\n\n\n\n\n\nProgram Description \nClick to Go to the Event Registration \nThe activity will focus on: \nEtiology \n\nDamage at any level to the fifth cranial nerve\, from the trigeminal nucleus to the corneal nerve endings\, may lead to the development of NK.\nSystemic diseases that may compromise trigeminal function\, such as diabetes\, multiple sclerosis\, and Leprosy\, may lead to the development of NK.\nWound healing after anterior segment surgery or trauma.\n\nPathophysiology \n\nCorneal nerves maintain corneal epithelial integrity\, proliferation\, and wound healing.\nIt has been postulated that corneal sensory nerve damage leads to marked changes in levels of neuromodulators that cause impairment in epithelial cell vitality and metabolism of the epithelial cells.\n\nEvaluation – The hallmark of NK is reduced or absent corneal sensation \n\nCochet-Bonnet or no-contact gas esthesiometer\nSlit lamp examination\nDilated fundus examination\n\nStaging – NK can be classified into three stages according to the Mackie classification. \n\nStage 1 – corneal epithelial changes with dry and cloudy epithelium\, superficial punctate keratopathy\, and corneal edema.\nStage 2 – recurrent and/or persistent epithelial defects with an oval or circular shape\, most frequently localized at the superior half of the cornea.\nStage 3 – corneal ulcer with stromal involvement that may be complicated by stromal melting and progression to corneal perforation.\n\nTreatment of NK – Treatment of NK depends on disease severity. \n\nTopical cenegermin – Cenegermin is currently the only medication approved for treating NK; it is approved for all stages.\n\nOther Treatment Options \n\nAntibiotics\nAutologous Serum Drops\nContact Lenses – Bandage contact lenses\, Scleral lenses\nTarsorrhaphy – Eyelids are partially or completely closed to protect the cornea and preserve tear fluid\, which is used to heal corneal ulcers\n\nAgenda \n\nOverview of the etiology\, pathophysiology\, recommended screening\, and testing procedures used in diagnosing NK – Walter Whitley\, OD\nDiscuss the efficacy and clinical utility of current and emerging treatments for early- and late-stage NK – Stephen C. Pflugfelder\, MD\n\nIntended Audience \nOphthalmologists\, optometrists\, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with neurotrophic keratitis \nCommercial Supporter \nSupported by an unrestricted educational grant from Dompé US Inc. \nLearning Objectives \n\nSummarize the etiology\, pathophysiology\, recommended screening\, and testing procedures used to establish a diagnosis of NK\nAssess the efficacy and clinical utility of current and emerging treatments for the early- and late-stage NK\n\nAccredited Providers \nAmedco and MedNet have collaborated to design and execute this activity. \n       \nJoint Accreditation Statement \nIn support of improving patient care\, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163. \nPhysicians (ACCME) Credit Designation \nAmedco LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nOptometrists Credit \nAmedco is accredited by COPE to provide continuing education to optometrists. \nAmedco designates this activity for a maximum of 1.25 COPE credit. \nAdditional Credit Information \nPhysician Assistants\nPAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. \nNurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.25 hours. \nDisclosures of Relationships With Ineligible Companies Policy \nIn accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education\, all faculty\, planning committee members\, and other individuals\, who are in a position to control content\, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance\, scientific objectivity\, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated. \nPlanners’ and Managers’ Disclosures \nAll relevant relationships have been reviewed and mitigated. \nOff-Label Disclosure Statement \nFaculty members are required to inform the audience when they are discussing off-label\, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity. \n\nFaculty \n \nWalter Whitley\, OD\, MBA\, FAAO\nVirginia Eye Consultants\nNorfolk\, VA \n \nStephen C. Pflugfelder\, MD\nProfessor and James and Margaret Elkins Chair in Ophthalmology\nBaylor College of Medicine\nHouston\, TX \nInstructions/Technical Requirements \nHardware: An internet-enabled computer\, smartphone\, tablet\, or other mobile device with audio and internet capabilities. \nSoftware: Installation of software like GoToWebinar may be necessary. \nCost \nThere are no fees for participating and receiving CME and COPE credit for this activity. \nContact \nBrian Waggoner\nProgram Manager\nMedNet\nbrianw@mmhus.net
URL:https://mednetus.net/event/advances-in-the-understanding-of-etiology-evaluation-and-management-of-neurotrophic-keratitis-2/
CATEGORIES:Live Program
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/q1gr1slaec0j-NK800x450.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250719T080000
DTEND;TZID=America/New_York:20250719T170000
DTSTAMP:20260423T152955
CREATED:20250620T065419Z
LAST-MODIFIED:20250620T065419Z
UID:10000011-1752912000-1752944400@mednetus.net
SUMMARY:New Paradigms in the Management of Hereditary Transthyretin Amyloidosis Mixed Phenotype (ATTRv): ATTRv-CM and ATTRv-PN
DESCRIPTION:July 19\, 2025 \nTake Me to the Event Registration\n\n\nEVENT Summary \nDates \nSaturday\, July 19\, 2025\, 10:00 AM ET\, 9:00 AM CT\, 8:00 AM MT\, and 7:00 AM PT \nLocation \nVirtual \nTarget Audience \nCardiologists\, neurologists\, geneticists\, radiologists\, primary care physicians\, nurse practitioners\, physician assistants\, and nurses who diagnose and treat patients with hereditary transthyretin amyloidosis \nFormat \nZoom Webinar \nCredits \n1.25 / AMA PRA Category 1 CreditsTM\n1.25 / ANCC Contact Hours \nCost \nFree \n\nProgram Description \nWebinar Registration – ZoomTake Me to the Event Registration \nThis program will provide up-to-date\, evidence-based information for diagnosing and managing ATTR-CM and ATTR-PN patients. The activity will focus on: \n\nATTR-CM and ATTR-PN – Frequency and characteristics of ATTR-CM and ATTR-PN\nDiagnosis of ATTR-CM\n\nNuclear scintigraphy (including Tc99m PYP\, Tc-99m DPD\, and Tc-99m HDMP)\nCardiovascular magnetic resonance (CMR)\nEchocardiography\nMagnetic resonance imaging (MRI)\nWestern blot assay\n\n\nDiagnosis of ATTR-PN\n\nScreening laboratory tests include blood glucose evaluations\, serum free light chain (FLC) serum B12 with metabolites\, and serum and urine immunofixation electrophoresis.\nTTR gene sequencing\, looking for TTR gene amyloidogenic variants\, and tools for detecting amyloid deposits.\nHistological documentation of amyloid in diagnosing ATTR.\nCongo red staining with apple green birefringence under polarized light represents the pathognomonic appearance of amyloid.\nSural nerve biopsy for confirming ATTRv-PN\, with a sensitivity of up to 86%.\nTarget organ biopsy offers the highest diagnostic yield; less invasive methods like abdominal fat aspiration or salivary gland biopsy are viable alternatives.\n\n\nTreatment of ATTR-CM and ATTR-PN- Novel treatment options for ATTR-CM and ATTR-PN\n\nTetramer stabilizers – Acoramidis\, Tafamidis\n\nAcoramidis\, FDA accepted the New Drug Application (NDA) on February 5\, 2024\, as an oral treatment for ATTR-CM.\nTafamidis is FDA-approved for treating wild-type ATTR (ATTRwt) and hereditary ATTR (ATTRv) cardiomyopathy.\n\n\nAntisense oligonucleotides – Eplontersen\, Inotersen\n\nEplontersen FDA accepted Fast track designation on Feb 8\, 2024\, for ATTR-CM\, and in December 2023\, eplontersen was approved for the treatment of ATTR-PN\nInotersen was FDA-approved for the treatment of ATTR-PN\n\n\nSmall interfering RNAs – Patisiran\, Vutrisiran\n\nPatisiran is approved for the treatment of ATTR-PN\nVutrisiran is approved for both the ATTR-CM and ATTR-PN\n\n\nNonsteroidal anti-inflammatory drug – Diflunisal\nInvestigational therapies include a TTR stabilizer\, AG10; 2 antifibril agents\, PRX004 and doxycycline/tauroursodeoxycholic acid; and 2 gene silencers\, vutrisiran and AKCEA-TTR-LRx; and clinical trials are ongoing.\n\n\n\nAgenda \n• Discuss the diagnosis and novel treatment options for ATTR-CM – Michelle Kittleson\, MD\, PhD \n• Discuss the diagnosis and novel treatment options for ATTR-PN – Chafic Karam\, MD \nIntended Audience \nCardiologists\, neurologists\, geneticists\, radiologists\, primary care physicians\, nurse practitioners\, physician assistants\, and nurses who diagnose and treat patients with hereditary transthyretin amyloidosis (ATTRv;v for variant)\, ATTR-CM and ATTR-PN. \nCommercial Supporter \nSupported by a restricted educational grant from Alnylam U.S.\, Inc. \nLearning Objectives \n\nSummarize the characteristics\, related disabilities\, comorbidities\, and variable disease presentations and course of hereditary transthyretin amyloidosis mixed phenotype\nAppraise nuclear scintigraphy’s role (including Tc99m PYP\, Tc-99m DPD\, and Tc-99m HDMP)\, genetic testing in diagnosing patients with suspected ATTR-CM and ATTR-PN\nIdentify novel treatment options for ATTR-CM and ATTR-PN with tetramer stabilizers\, antisense oligonucleotides\, and small interfering RNAs\nImplement interdisciplinary care for patients with ATTR-CM and ATTR-PN\, incorporating primary and specialty care\, supportive ancillary services\, and shared decision-making.\n\nAccredited Providers \nJointly Accredited by Haymarket Medical Education and MedNet \n   \nJoint Accreditation Statement \nIn support of improving patient care\, this activity has been planned and implemented by Haymarket Medical Education and MedNet. Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to provide continuing education for the healthcare team. Haymarket Medical Education Joint Accreditation #JA4008232. \nPhysicians (ACCME) Credit Designation \nHaymarket Medical Education designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nNurses \nThis activity is awarded 1.25 contact hours (based on 60 minutes per contact hour). \nAdditional Credit Information \nPhysician Assistants\nPAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. \nNurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allows reciprocity for AANPCP continuing education credit. 1.25 hours. \nDisclosures of Relationships with Ineligible Companies Policy \nIn accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education\, all faculty\, planning committee members\, and other individuals\, who are in a position to control content\, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance\, scientific objectivity\, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated. \nPlanners’ and Managers’ Disclosures \nAll relevant relationships have been reviewed and mitigated. \nOff-Label Disclosure Statement \nFaculty members are required to inform the audience when they are discussing off-label\, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity. \nFaculty \n \nMichelle M. Kittleson\, M.D.\, Ph.D.\nDirector of Education in Heart Failure and Transplantation\nProfessor of Medicine\nSmidt Heart Institute\, Cedars-Sinai\nLos Angeles\, CA \nDr. Kittleson has no relevant financial relationships with ineligible companies to disclose. \n \nChafic Karam\, MD\nProfessor of Clinical Neurology\nChief\, Neuromuscular Division\nDirector\, Neuromuscular Fellowship\nDepartment of Neurology\nUniversity of Pennsylvania\nPhiladelphia\, PA \nDr. Karam reports the following relevant financial relationships with ineligible companies to disclose:\nConsultant: Alnylam\, AstraZeneca\, Novo Nordisk\, Alexion\, Corino\, and Pfizer\nResearch Support: Ionis \nInstructions/Technical Requirements \nHardware: An internet-enabled computer\, smartphone\, tablet\, or other mobile device with audio and internet capabilities. \nSoftware: Installation of software like Zoom may be necessary. \nCost \nThere are no fees for participating and receiving CME and CE credit for this activity. \nContact \nBrian Waggoner\nProgram Manager\nMedNet\nbrianw@mmhus.net
URL:https://mednetus.net/event/new-paradigms-in-the-management-of-hereditary-transthyretin-amyloidosis-mixed-phenotype-attrv-attrv-cm-and-attrv-pn/
CATEGORIES:Live Program
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/n81qh2gf0iyb-ATTRvLive800x450.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251115T082500
DTEND;TZID=America/New_York:20251115T123000
DTSTAMP:20260423T152955
CREATED:20250815T162214Z
LAST-MODIFIED:20251103T191354Z
UID:10000021-1763195100-1763209800@mednetus.net
SUMMARY:Changing Landscape of Management in Eye Diseases: Glaucoma\, Ocular Surface Disease\, Neurotrophic Keratitis\, Cataract Surgery\, and Vitreoretinal Surgery
DESCRIPTION:
URL:https://mednetus.net/event/changing-landscape-of-management-in-eye-diseases-glaucoma-ocular-surface-disease-neurotrophic-keratitis-cataract-surgery-and-vitreoretinal-surgery/
LOCATION:Zoom Live Webinar\, United States
CATEGORIES:Live Program
END:VEVENT
END:VCALENDAR